Drug Profile
Research programme: obesity therapy - Verva Pharmaceuticals
Alternative Names: IMPDH inhibitor - VervaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Verva Pharmaceuticals
- Class Small molecules
- Mechanism of Action Inosine monophosphate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in Australia (PO)
- 30 Oct 2008 Preclinical trials in Obesity in Australia (unspecified route)